There is no experience with overdose in clinical studies. Denosumab has been administered in clinical studies using doses up to 180 mg every 4 weeks (cumulative doses up to 1,080 mg over 6 months) and no additional adverse reactions were observed.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
